drugset
drugset / Trial / NCT00192153

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

NCT00192153 ↗

Phase 2 Completed 240 enrolled MedImmune LLC Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this clinical study was to evaluate immune responses measuring antibodies in serum and secretions and cellular immune responses generated by CAIV-T vaccine in healthy adults aged 18 years and older as a means to develop assays for application in investigating potential immunological correlates of protection and/or establishing assays to measure vaccine take.

Timeline

Start
2001-07
Primary completion
—
Completion
2001-10

Drugs

EvaluationDrugModalityDoseRoute
Subject FluMist Vaccine — —
Subject TIV Unknown — —

Indications

influenza